Tag: Janssen

FDA Advisory Committee Voted For Janssen Depression Drug

The Janssen Pharmaceutical Companies of Johnson & Johnson has announced that the U.S. Food and Drug Administration (FDA) Psychopharmacologic Drug Advisory Committee and Drug Safety and Risk Manage...

Janssen and MeiraGTx to Work on Inherited Retinal Diseases

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced a worldwide collaboration and license agreement with MeiraGTx Holdings plc, a clinical-stage gene therapy company, to deve...

Philogen and Janssen Discover New Molecular Therapy

Philogen S.p.A., a privately-owned biotechnology company, today announced through its wholly-owned Swiss subsidiary, Philochem AG, a collaboration agreement with Janssen Biotech, Inc., one of the Jans...

Janssen Has EC Approval for nmCRPC Drug

The Janssen Pharmaceutical Companies of Johnson & Johnson has secured marketing approval from the European Commission (EC) for Erleada (apalutamide) to treat non-metastatic castration-resistant pr...

Janssen and Locus Unite for Bacterial Infections Treatment

Janssen Pharmaceuticals has signed an exclusive collaboration and licence agreement with biotechnology firm Locus Biosciences for CRISPR products intended to treat bacterial infections. The partner...

The Oxford Science Park is to house the Vaccines Manufacturing Innovation Centre

Pharma companies are industrial partners of Britain's first facility dedicated to innovation in vaccines manufacturing. Located on a new plot close to the Magdalen Centre, home to many SMEs, the £6...

Aro Biotherapeutics receives funding to develop its protein drug platform

Aro Biotherapeutics, a newly established biotechnology company, has raised $13 million in start-up investment to develop and commercialize Centyrins, an innovative protein drug platform.

Janssen signs collaboration and license agreement with Dutch biotech

drug discovery
argenx, a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies announced an exclusive agreement with Janssen.

Korean pharma company Yuhan signs licensing deal with Janssen

Yuhan Corporation entered into a licensing agreement with Janssen Biotech to develop Lazertinib, a treatment for non-small cell lung cancer (NSCLC) that is undergoing clinical trials in Korea.

Johnson & Johnson launches a new vaccines facility in the Netherlands

Johnson & Johnson unveiled a new vaccines launch facility that represents a significant investment in novel vaccines development, global health and security, and pandemic preparedness efforts.

Genmab’s cancer treatment shows promising results

cancer lab diagnostic
A new cancer treatment developed by Genmab has shown positive results in a phase 3 study. The treatment could potentially be offered as a first-line treatment for leukemia and multiple melanoma.

Janssen will develop a new treatment for chronic hepatitis B

janssen j&j
Janssen Pharmaceuticals has entered into an agreement with Arrowhead Pharmaceuticals (USA) for an exclusive, worldwide license to develop and commercialize ARO-HBV.

Janssen and Bayer will close their South Korean facilities

Janssen and Bayer will join global pharmaceutical companies that have pulled their manufacturing facilities out of Korea over rising payroll costs and intensifying conflicts with unions.

EUSA Pharma buys global rights to Sylvant drug from Janssen

EUSA Pharma announced that it has entered into a definitive agreement with Janssen Sciences Ireland UC, a subsidiary of Janssen R&D Ireland to acquire the global rights to SYLVANT® (siltuximab).

Janssen stops the trials of Daratumumab

janssen j&j
Genmab announced that the DMC has recommended that the Phase Ib/II study of daratumumab in combination with atezolizumab versus atezolizumab monotherapy should be terminated.

Janssen Biotech will buy BeneVir Biopharm

Janssen Biotech, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, will acquire BeneVir Biopharm, a privately-held, biopharmaceutical company specializing in the development of oncolytic immunotherapies.